

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT EXCLUSIVE DISTRIBUTION COOPERATION BETWEEN GAUSH NEOTECH AND HEIDELBERG

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Neotech Ltd* (高視創新科技有限公司) (“**Gaush Neotech**”), a subsidiary of the Company, entered into a five-year exclusive agency agreement with HEIDELBERG ENGINEERING GmbH of Germany (“**HEIDELBERG**”) in respect of T3 corneal confocal microscopy, a product independently developed and manufactured by Gaush Neotech. Pursuant to such agreement, HEIDELBERG will be the exclusive distributor of the relevant products worldwide, excluding the People’s Republic of China, and will also be responsible for market promotion and corresponding technical services.

The T3 corneal confocal microscopy, independently developed and manufactured by Gaush Neotech, can observe the cornea and conjunctiva in vivo, and assist in the diagnosis of various corneal and conjunctival diseases (such as infectious diseases, non-infectious diseases including corneal degeneration, malnutrition, immune lesions and keratoconus, as well as surgery-related, traumatic, dry eye, and systemic disease-related corneal lesions, etc.), providing a basis for disease diagnosis and condition assessment.

HEIDELBERG is a globally leading provider of ophthalmic diagnostic solutions headquartered in Germany. Since the Company’s establishment in 1998, it has acted as the exclusive distributor of HEIDELBERG’s ophthalmic imaging systems in China, and the two parties have maintained a mutually important business partnership.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, August 17, 2026

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Ms. Cheng Juan, Mr. Yubing Li and Ms. Qiu Xiaoling as independent non-executive Directors.